Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James D Chambers

Showing results (31-40 of 92) with videos related to

Pageof 10
Sort By:
JAMA Network Open|August 15, 2023
Follow-On Indications for Orphan Drugs Related to the Inflation Reduction ActJames D Chambers, Katherine A Clifford, Daniel E Enright, et al.
Health Affairs (Project Hope)|September 3, 2024
US Commercial Plans Increase Choice Of Biosimilar And Originator Products; Market Net Prices DecreaseMolly T Beinfeld, Fariel LaMountain, William Wong, et al.
The American Journal of Managed Care|September 20, 2023
Varied use of step therapy among Medicare Advantage plansNola B Jenkins, Donald E Nichols, Daniel E Enright, et al.
The American Journal of Managed Care|October 9, 2014
Potential role of network meta-analysis in value-based insurance designJames D Chambers, Aaron Winn, Yue Zhong, et al.
Journal of Managed Care & Specialty Pharmacy|September 27, 2016
Variation in Private Payer Coverage of Rheumatoid Arthritis DrugsJames D Chambers, Colby L Wilkinson, Jordan E Anderson, et al.
Health Affairs (Project Hope)|November 1, 2021
Variation In Use And Content Of Prescription Drug Step Therapy Protocols, Within And Across Health PlansKelly L Lenahan, Donald E Nichols, Rebecca M Gertler, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 2, 2023
Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health PlansTianzhou Yu, Shihan Jin, Chang Li, et al.
Health Policy (Amsterdam, Netherlands)|February 20, 2013
What can we learn from the U.S. expanded end-stage renal disease bundle?James D Chambers, Daniel E Weiner, Sarah K Bliss, et al.
Journal of Managed Care & Specialty Pharmacy|November 28, 2018
Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage PoliciesJames D Chambers, Elle F Pope, Colby L Wilkinson, et al.
Health Affairs (Project Hope)|October 8, 2014
Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugsJames D Chambers, Teja Thorat, Junhee Pyo, et al.
Pageof 10

Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
JAMA Network Open|August 15, 2023
Follow-On Indications for Orphan Drugs Related to the Inflation Reduction ActJames D Chambers, Katherine A Clifford, Daniel E Enright, et al.
Health Affairs (Project Hope)|September 3, 2024
US Commercial Plans Increase Choice Of Biosimilar And Originator Products; Market Net Prices DecreaseMolly T Beinfeld, Fariel LaMountain, William Wong, et al.
The American Journal of Managed Care|September 20, 2023
Varied use of step therapy among Medicare Advantage plansNola B Jenkins, Donald E Nichols, Daniel E Enright, et al.
The American Journal of Managed Care|October 9, 2014
Potential role of network meta-analysis in value-based insurance designJames D Chambers, Aaron Winn, Yue Zhong, et al.
Journal of Managed Care & Specialty Pharmacy|September 27, 2016
Variation in Private Payer Coverage of Rheumatoid Arthritis DrugsJames D Chambers, Colby L Wilkinson, Jordan E Anderson, et al.
Health Affairs (Project Hope)|November 1, 2021
Variation In Use And Content Of Prescription Drug Step Therapy Protocols, Within And Across Health PlansKelly L Lenahan, Donald E Nichols, Rebecca M Gertler, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 2, 2023
Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health PlansTianzhou Yu, Shihan Jin, Chang Li, et al.
Health Policy (Amsterdam, Netherlands)|February 20, 2013
What can we learn from the U.S. expanded end-stage renal disease bundle?James D Chambers, Daniel E Weiner, Sarah K Bliss, et al.
Journal of Managed Care & Specialty Pharmacy|November 28, 2018
Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage PoliciesJames D Chambers, Elle F Pope, Colby L Wilkinson, et al.
Health Affairs (Project Hope)|October 8, 2014
Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugsJames D Chambers, Teja Thorat, Junhee Pyo, et al.
Pageof 10